Uppsala, Sweden, May 4 2017. Biovica has received an order for the company’s product DiviTum® from a global contract research company (CRO company), commissioned by a global pharmaceutical company to study the effectiveness of new cancer drugs.
The value of the order is approximately one million SEK . The order is one of several from the same customer and so far, the second largest Biovica has received.
“We are very pleased that leading actors in the industry see the value of our product and use DiviTum® in their evaluation of new drugs. This is in line with our ambition to participate in the development of new cancer drugs and to contribute to the best possible treatment outcome for cancer patients. “, says Anders Rylander, CEO Biovica.
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
I the event of inconsistency or discrepancy between the Swedish press release and the English translation of the Swedish press release, the Swedish press release takes precedence.
This information is information that Biovica International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person(s) set out above, at 10.00 CET on May 4 2017.
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.